A-192621 |
A-192621 : Antagonist of EDNRB
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download
Probe Summary
| Targets | Biochemical/Biophysical Potency | Cellular Potency |
|---|---|---|
| EDNRB |
|
|
Antagonist
in some publications a dose of 30 mg/kg/d in mouse and rat has been used
0-300 nM
Selectivity
In Vitro Selectivity Assessment
Selectivity Assessment Description:
Selectivity within target family: Surpasses criterion: > 600-fold selective against EDNRA (IC50 for ...
Potency Cellular
In Vitro
EDNRB
Mode of Action: Antagonist
Structure-Activity-Relationship data available? No
DOI Reference: 10.1042/CS103S107S
In Vivo Validations
Rat
Dose: 5 mg/Kg IV, 10 mg/Kg PO
Route of delivery:
Intravenous, oral
Plasma half life:
5h PO
Cmax:
0.81 ug/mL
Area Under the Curve::
3.60 IV, 2.51 PO µg*h/mL
Bioavailability:
34.9%
DOI Reference: 10.1042/CS103S112S
Dog
Dose: 5 mg/Kg IV, 10 mg/Kg PO
Route of delivery:
Intravenous, Oral
Plasma half life:
2h PO
Cmax:
0.38 ug/mL
Area Under the Curve::
4.07 (IV), 0.45 (PO) µg*h/mL
Bioavailability:
11%
DOI Reference: 10.1042/CS103S112S
Monkey (Cynomolgus)
Dose: 5 mg/Kg IV, 10 mg/Kg PO
Plasma half life:
3.1 h
Cmax:
0.19 ug/mL
Area Under the Curve::
5.25 (IV), 0.68 (PO) µg*h/mL
Bioavailability:
13%
DOI Reference: 10.1042/CS103S112S
Negative Control Compounds
A-1806262
Notes: The control enantiomer A-1806262 is about 150-fold selective compared to probe.
Chemical Information
| Molecular Formula | C33H38N2O6 |
| SMILEs | CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1 |
| InChI | InChI=1S/C33H38N2O6/c1-4-16-39-25-13-10-23(11-14-25)32-30(33(37)38)26(24-12-15-27-28(17-24)41-20-40-27)18-35(32)19-29(36)34-31-21(5-2)8-7-9-22(31)6-3/h7-15,17,26,30,32H,4-6,16,18-20H2,1-3H3,(H,34,36)(H,37,38)/t26-,30-,32+/m1/s1 |
| Molecular weight | 558.27 Da |
| AlogP | 5.8089 |
| HBond acceptors | 8 |
| HBond donors | 2 |
| Atoms | 79 |
References
Publications
Vendors
Note: This is not an exhaustive list and does not indicate endorsement by the portal.